Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms.

Han Q, Zheng B, Daines L, Sheikh A. · 2022

Read Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms. by Han Q, Zheng B, Daines L, Sheikh A. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8875269.txt.

Introduction

Han, Zheng, Daines, and Sheikh pool one-year follow-up data on symptoms after COVID-19. Many survivors report problems long after infection. How many still suffer at one year was unclear. The team searched PubMed and Embase for long follow-up studies. Eighteen papers qualified. Together they covered 8,591 survivors. Random-effects meta-analysis produced pooled rates for each symptom.

Fatigue or weakness led the list at 28%. Joint and muscle pain followed at 26%. Depression sat at 23% and anxiety at 22%. Breathlessness affected 18%, and memory loss 19%. Insomnia was lowest among the leaders at 12%. Women reported more lingering symptoms than men. So did patients whose first illness was severe. The authors urge work on causes and targeted care. Long COVID, they show, is no small tail.

Catalog record

CREATORHan Q, Zheng B, Daines L, Sheikh A.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE34 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8875269

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms By Qing Han, Bang Zheng, Luke Daines, Aziz Sheikh, Wenjun Ma, Alexander WE Franz Published in: Pathogens DOI: 10.3390/pathogens11020269 ABSTRACT Abstract Emerging evidence has shown that COVID-19 survivors could suffer from persistent symptoms. However, it remains unclear whether these symptoms persist over the longer term. This study aimed to systematically synthesise evidence on post-COVID symptoms persisting for at least 12 months. We searched PubMed and Embase for papers reporting at least one-year follow-up results of COVID-19 survivors published by 6 November 2021. Random-effects meta-analyses were conducted to estimate pooled prevalence of specific post-COVID symptoms. Eighteen papers that reported one-year follow-up data from 8591 COVID-19 survivors were included. Fatigue/weakness (28%, 95% CI: 18–39), dyspnoea (18%, 95% CI: 13–24), arthromyalgia (26%, 95% CI: 8–44), depression (23%, 95% CI: 12–34), anxiety (22%, 95% CI: 15–29), memory loss (19%, 95% CI: 7–31), concentration difficulties (18%, 95% CI: 2–35), and insomnia (12%, 95% CI: 7–17) were the most prevalent symptoms at one-year follow-up. Existing evidence suggested that female patients and those with more severe initial illness were more likely to suffer from the sequelae after one year. This study demonstrated that a sizeable proportion of COVID-19 survivors still experience residual symptoms involving various body systems one year later. There is an urgent need for elucidating the pathophysiologic mechanisms and developing and testing targeted interventions for long-COVID patients. Keywords: post-acute sequelae of COVID-19, long-COVID, prevalence, symptom, meta-analysis 1. INTRODUCTION Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still rapidly spreading around the world, fuelled by the emergence of new variants. According to the World Health Organization (WHO) Coronavirus (COVID-19) Dashboard [1], there have been over 300 million confirmed cases of COVID-19 worldwide. A feature of COVID-19 that differs from other respiratory infections could be its multi-system symptomatology, complications, and long-term sequelae [2]. A growing body of evidence has shown that COVID-19 survivors may experience persistent symptoms affecting different organ systems after the acute phase of infection (also known as long-COVID [3]). Several previous systematic reviews and meta-analyses on long-COVID [2,4,5] estimated the prevalence of short- and medium-term persistent symptoms after COVID-19 infection, involving respiratory, cardiovascular, musculoskeletal, integumentary, gastrointestinal, endocrine, and neurological systems. A meta-analysis [4] of 33 papers investigating hospitalised and non-hospitalised COVID-19 survivors demonstrated that 63.2%, 71.9%, and 45.9% of patients experienced at least one persistent symptom at 30, 60, and ≥ 90 days after hospitalisation or onset, of which fatigue, dyspnoea, cough, anosmia, ageusia, and joint pain were the most prevalent symptoms. A meta-analysis [5] of 39 studies with up to seven months follow-up showed that the most frequently reported symptoms included weakness, fatigue, concentration impairment, and breathlessness. Another meta-analysis [2] of 15 papers reported over 50 persistent symptoms of COVID-19 experienced by COVID-19 survivors between 14–110 days post infection. However, no previous systematic review and meta-analysis has focused on longer-term persistent symptoms of COVID-19, and it remains unclear to what extent these broad classes of symptoms still persist after one year post infection. With the emerging data of longer-term follow-up of COVID-19 patients, it is important to investigate the natural history of COVID-19 symptomatology and whether the spectrum of long-lasting symptoms is different from that of the short- or medium-term manifestations previously described. We sought to systematically synthesise existing evidence on long-term post-COVID symptoms. We estimated the pooled prevalence and also summarised potential risk factors of post-COVID symptoms lasting for one year after infection. 2. MATERIALS AND METHODS 2.1. Search Strategy The reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline [6]. We systematically searched PubMed and Embase databases for studies reporting one-year follow-up data for COVID-19 survivors published between 1 January 2021 and 6 November 2021, in English or Chinese. Studies were identified using search terms related to COVID-19, sequelae, and long-term follow-up. Medical Subject Headings (MeSH) terms and free text words were combined for the searches. Reference lists of relevant papers were checked for additional studies. Our detailed search strategies are presented in the Supplementary Methods. Two authors (Q.H. and B.Z.) independently screened the papers and performed data extraction and quality assessment. Any discrepancies were resolved following review of the corresponding papers by both authors and consensus discussion. 2.2. Inclusion/Exclusion Criteria Studies were included if they used a cohort, cross-sectional, or case series design and reported data required for the estimation of pooled prevalence of post-COVID symptoms (i.e., sample size of COVID-19 survivors and the prevalence or proportion of specific symptoms). Eligible studies were required to have a mean/median follow-up time of at least 12 months. For studies with overlapping or identical participants, we included the study with the largest sample size. Studies were excluded from meta-analysis if they only recruited participants with reported residual symptoms or complications post COVID-19 or only recruited participants with a specific comorbidity (e.g., cancer patients). We also excluded studies with less than 50 COVID-19 survivors because of concerns regarding the precision and potential bias of prevalence estimates. Review papers without original data and conference abstracts without full text were excluded from this study. 2.3. Data Extraction We extracted the following information from eligible studies: (1) sample size and prevalence or number of patients with specific post-COVID symptoms; (2) types and definitions of post-COVID symptoms; (3) follow-up period and follow-up method; and (4) population characteristics (country, age, sex, and severity of COVID-19 infection). We used the Cochrane recommended software PlotDigitizer (www.plotdigitizer.sourceforge.net/, accessed on 15 January 2022) to extract graphically presented prevalence data from two papers. We also extracted results of risk factor analyses (if available) for a qualitatively synthesis of the risk factors for long-term post-COVID symptoms. 2.4. Study Quality Assessment The study quality of eligible papers was evaluated using the “Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Studies Reporting Prevalence Data” [7]. This checklist consists of nine items with four options (i.e., yes, no, unclear, not applicable). We assigned an overall quality rating of high, moderate, or low to each paper based on a qualitative evaluation of the nine items. 2.5. Statistical Analyses Random-effects meta-analyses with inverse-variance method were conducted to estimate the pooled prevalence and its confidence interval (CI) of specific post-COVID symptoms in COVID-19 survivors [8]. The study-specific confidence intervals were estimated using the Wilson’s score method [8]. The meta-analyses were conducted only for symptoms assessed by three or more studies. The heterogeneity of prevalence estimates across studies was assessed by the I2 statistic and Q test in each analysis. For each symptom with > 10 studies, a funnel plot for prevalence estimates after logit transformation was created to graphically identify publication bias, followed by an Egger’s test of asymmetry. To examine the robustness of the main findings, several sensitivity analyses were performed by: (1) excluding studies rated as poor quality and (2) repeating the meta-analyses using prevalence estimates after logit transformation or Freeman–Tukey double-arcsine transformation [8]. We also assessed the influence of each study on the overall estimate by recalculating the pooled prevalence after removing that study. Statistical analyses were performed using Stata (version 14, StataCorp, College Station, TX, USA). All statistical tests were two-sided with the significance threshold of p < 0.05. 3. RESULTS 3.1. Search

Read the complete text